ArticleInternational journal of clinical and experimental pathology2015

Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.

Huanhuan Li et al.PubMed ↗Full text ↗

No numbers read from the abstract.